BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Chemaphor Inc. (CFR.TO) and National Research Council of Canada Receive Funding Support for Joint Project from Prince Edward Island Government


8/19/2009 9:59:12 AM

OTTAWA, CANADA--(Marketwire - August 19, 2009) - A joint research proposal from Chemaphor (TSX VENTURE: CFR) and the National Research Council of Canada Institute for Nutrisciences and Health (NRC-INH) has received funding support from the Government of Prince Edward Island (PEI). The research proposal to evaluate the effects of oxidized beta-carotene ((-carotene), otherwise known as OxBC, on gut immunity is funded through the Province's Discovery and Development Fund.

This new project directly builds on the results of Chemaphor and NRC-INH's recent collaborative pilot study funded through the Innovation PEI Pilot Fund, which demonstrated OxBC's ability to enhance the intestinal immune system of mice.

With financial support of approximately $90,000 from PEI's Discovery and Development Fund, the new project aims to develop and implement genomic-based technologies that will be used to more broadly evaluate OxBC's effects on the mouse intestinal immune system. Although modeled on mice, this research has the potential to lay the foundation for the use of OxBC as a novel gut immune system enhancer for other animals, with potential benefits that include providing a promising alternative to antibiotic use in feeds in the agriculture and aquaculture sectors.

In closing, Dr Paul Dick, CEO of Chemaphor, comments that "By Chemaphor and the NRC working together, we grow stronger in conducting innovative research, which in turn drives product innovation. Receiving financial support from the government of Prince Edward Island completes the picture. This project is an excellent example of when public, private and government partners work together, each party benefits and value is created."

About Chemaphor

Chemaphor Inc. (www.chemaphor.com) uses its core expertise in chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, Chemaphor's beliefs, plans, objectives, strategies, estimates, intentions and expectations. Actual results and events may differ materially from those included in, contemplated or implied by such forward looking statements for a variety of reasons. When used in this press release, the words "seek", "believe", "develop", "intends", "will", "may", "potential", "should" and similar expressions are intended to be among the statements that identify forward-looking statements. Forward-looking statements are subject to inherent risks and uncertainties including, but not limited to, market and general economic conditions, the availability to attract and retain key personnel, the availability and terms of financing, the scientific and commercial viability of planned products, changes in Chemaphor's relationship with its key suppliers and partners, competitive factors, changes in regulatory environments affecting Chemaphor's business, and the accuracy in management's assumptions. This list is not exhaustive of the factors that may affect any of Chemaphor's forward-looking statements. Investors and others should carefully consider these and other factors and not place undue reliance on these forward-looking statements. In addition, these forward-looking statements relate to the date on which they were made and Chemaphor disclaims and has no intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. (Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.)


Contacts:
Chemaphor
Dr. Graham Burton
613-990-0969
g.burton@chemaphor.com

Evolution Group Inc.
514-448-4887
Toll Free: 866-703-4887
514-906-2428 (FAX)
www.evolutiongrp.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->